Short Interest in Pulmatrix Inc (NASDAQ:PULM) Rises By 18.9%

Pulmatrix Inc (NASDAQ:PULM) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 710,300 shares, an increase of 18.9% from the June 30th total of 597,500 shares. Currently, 9.3% of the company’s stock are short sold. Based on an average daily trading volume, of 344,000 shares, the days-to-cover ratio is currently 2.1 days.

A number of equities research analysts have recently commented on PULM shares. Zacks Investment Research cut shares of Pulmatrix from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. HC Wainwright reiterated a “buy” rating on shares of Pulmatrix in a report on Tuesday, April 16th. Finally, ValuEngine upgraded shares of Pulmatrix from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th.

Shares of NASDAQ:PULM remained flat at $$0.85 during trading on Tuesday. 51,646 shares of the stock were exchanged, compared to its average volume of 134,410. The company has a 50-day simple moving average of $0.90. Pulmatrix has a 1 year low of $0.72 and a 1 year high of $4.70. The company has a market cap of $16.65 million, a P/E ratio of -0.17 and a beta of 1.31.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.01). Equities research analysts forecast that Pulmatrix will post -1.9 EPS for the current fiscal year.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Read More: What is systematic risk?

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with's FREE daily email newsletter.